$5650 | Single User
$6650 | Multi User
$8150 | Corporate License
$10000 | Global License

Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019
[Lowest Price Guaranteed: $5,650]

Published by MarketsandMarkets: 30 Jan 2015 | 41282 | In Stock

Introduction

The global preclinical imaging market is estimated to grow at a CAGR of 6.0% from 2014 to 2019. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the preclinical imaging market in 2014, the Asia-Pacific region is poised to grow at the highest CAGR of 8.2% in the next five years. Factors such as increased outsourcing of preclinical research activities to Asia-based CROs by big pharmaceutical and biotechnological companies, owing to low cost of research in these nations; and increased government funding for drug discovery and development activities in economically emerging counties are propelling the growth of the preclinical imaging market in Asia-Pacific region.

The growth of the global preclinical imaging market is driven by factors such as development of technologically advanced hybrid preclinical imaging systems such as PET/CT, PET/MRI, and PET/SPECT/CT; growing acceptance of preclinical imaging as a legitimate drug development tool; and rising volume of preclinical research. In addition, emerging markets offering lucrative growth and departure of major companies from preclinical imaging systems market are creating new growth opportunities for the preclinical imaging systems and reagents manufacturers. Nonetheless, declining NIH (National Institutes of Health) funding for life science research, high implementation cost of preclinical imaging devices, and high cost and data requirements for bringing new imaging technology are the key reasons hampering the growth of preclinical imaging market.

In this report, the preclinical imaging market has been segmented on the basis of modality (covering optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems), by type of reagents (including nuclear imaging reagents, optical imaging reagents, MRIcontrast agents, ultrasound contrast agents and CT contrast agents), and by region (North America, Europe, Asia Pacific, and Rest of the World). The optical imaging systems market is estimated to account for the largest share of the global preclinical imaging systems market in 2014. However, the nuclear imaging systems segment is expected to grow at the highest rate during the forecast period. Factors such as development of technologically advanced hybrid nuclear imaging systems such as PET/MRI and PET/SPECT/CT and rising adoption of these devices in the preclinical research are driving the grow of the preclinical nuclear imaging systems market.

Geographically, North America (comprising the U.S. and Canada) commands the largest share of 36.2% of the global preclinical imaging market in 2014, followed by Europe. The preclinical imaging market in North America is primarily driven by various factors high volume of preclinical research in this region, easy availability and accessibility of resources (such as radioactive tracers), and rising government funding for research and innovation in Canada.

However, declining funding budgets of the U.S. National Institutes of Health (NIH) for preclinical research studies and recent changes in the Canadian R&D tax credit program are negatively affecting the growth of preclinical imaging market in North America.

The global preclinical imaging market is highly fragmented and competitive with a large number of global and local manufacturers of preclinical imaging systems and reagents. As of 2013, the global preclinical imaging market was dominated by PerkinElmer, Inc. (U.S.) and Bruker Corporation (U.S.), which together accounted for ~45% share of the market. New product launches, partnerships, agreements, collaborations, and geographic expansions were the major strategies adopted by most of the market players to achieve growth in the preclinical imaging market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis —industry analysis (industry trends, and Porter’s five force model), market share analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preclinical imaging systems and reagents market, high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on preclinical imaging products offered by the top 10 players in the preclinical imaging market. The report analyzes the preclinical imaging market by modality and type of reagent across four geographies

• Product Development/Innovation: Detailed insights on current and upcoming technologies, research and development activities, and new product launches in the preclinical imaging market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preclinical systems and reagents across geographies

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the preclinical systems and reagents market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the preclinical systems and reagents market

Table of Contents
for Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

  • TABLE OF CONTENTS

    1 INTRODUCTION 18

    1.1 OBJECTIVES OF THE STUDY 18

    1.2 MARKET DEFINITION 19

    1.3 MARKET SCOPE 19

    1.3.1 LIMITATION 19

    1.3.2 MARKETS COVERED 19

    1.3.3 YEARS CONSIDERED FOR THE STUDY 21

    1.4 CURRENCY 21

    1.5 STAKEHOLDERS 21

    2 RESEARCH METHODOLOGY 22

    2.1 RESEARCH DATA 22

    2.1.1 SECONDARY DATA 22

    2.1.1.1 Key Data From Secondary Sources 23

    2.1.2 PRIMARY DATA 23

    2.1.2.1 Breakdown of Primaries 24

    2.1.2.2 Key Data From Primary Sources 24

    2.1.2.3 Key Industry Insights 25

    2.2 MARKET SIZE ESTIMATION 25

    2.2.1.1 Bottom-up Approach 25

    2.2.1.2 Top-down Approach 26

    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 27

    2.4 RESEARCH ASSUMPTIONS & LIMITATIONS 29

    2.4.1 ASSUMPTIONS 29

    2.4.2 LIMITATIONS 29

    3 EXECUTIVE SUMMARY 30

    3.1 INTRODUCTION 30

    3.2 CURRENT SCENARIO 31

    3.3 FUTURE OUTLOOK 32

    3.4 CONCLUSION 34

    4 PREMIUM INSIGHTS 35

    4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE PRECLINICAL IMAGING MARKET 35

    4.2 PRECLINICAL IMAGING REAGENTS MARKETS, BY REGION (2014) 36

    4.3 GLOBAL PRECLINICAL IMAGING SYSTEMS, BY REGION (2014) 37

    4.4 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, (2014–2019) 38

    5 MARKET OVERVIEW 39

    5.1 INTRODUCTION 39

    5.2 MARKET SEGMENTATION 39

    5.2.1 BY MODALITY 40

    5.2.2 BY REAGENT 41

    5.3 MARKET DYNAMICS 41

    5.3.1 DRIVERS 42

    5.3.1.1 Advancements in molecular imaging technologies 42

    5.3.1.2 Growing acceptance of preclinical imaging as a legitimate drug development tool 43

    5.3.1.3 Increasing demand for multi-modality imaging technologies in preclinical research 44

    5.3.1.4 Increasing number of preclinical research activities 44

    5.3.2 RESTRAINTS 45

    5.3.2.1 High implementation costs of imaging systems 45

    5.3.2.2 Reduced NIH funding for life science research activities 45

    5.3.2.3 High cost and data requirements for developing new imaging technologies 46

    5.3.3 OPPORTUNITIES 46

    5.3.3.1 Emerging markets offer lucrative growth opportunities for market players 46

    5.3.3.2 Major companies exiting from the preclinical imaging market is opening new growth avenues for existing market players 47

    5.3.3.3 Integration of preclinical MRI systems with other imaging modalities 48

    5.3.3.4 Development of low-cost imaging devices with high resolution and sensitivity 48

    5.3.4 CHALLENGES 48

    5.3.4.1 Technological limitations of standalone preclinical imaging modalities 48

    5.3.4.2 Challenges associated with the application of radioisotopes negatively affects the demand of micro-PET systems 49

    6 INDUSTRY INSIGHTS 50

    6.1 INTRODUCTION 50

    6.2 VALUE CHAIN ANALYSIS 50

    6.3 SUPPLY CHAIN ANALYSIS 51

    6.3.1 KEY STAKEHOLDERS 52

    6.3.2 KEY INFLUENCERS 52

    6.4 INDUSTRY TRENDS 53

    6.4.1 RISING FOCUS OF MARKET PLAYERS TOWARDS THE DEVELOPMENT OF HYBRID PRECLINICAL IMAGING SYSTEMS 53

    6.4.2 INCREASING GOVERNMENT FUNDING FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT IN EMERGING NATIONS 53

    6.5 PORTER’S FIVE FORCES ANALYSIS 54

    6.5.1 THREAT FROM NEW ENTRANTS 54

    6.5.2 THREAT FROM SUBSTITUTES 55

    6.5.3 BARGAINING POWER OF SUPPLIERS 55

    6.5.4 BARGAINING POWER OF BUYERS 56

    6.5.5 INTENSITY OF COMPETITIVE RIVALRY 56

    7 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY 57

    7.2 INTRODUCTION 58

    7.3 OPTICAL IMAGING SYSTEMS 59

    7.3.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS 62

    7.3.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS 63

    7.3.3 OPTICAL + X-RAY/OPTICAL + CT 65

    7.4 PRECLINICAL NUCLEAR IMAGING SYSTEMS 66

    7.4.1 MICRO-PET SYSTEMS 69

    7.4.1.1 Standalone PET Systems 71

    7.4.1.2 PET/CT Systems 71

    7.4.1.3 PET/MRI Systems 72

    7.4.2 MICRO-SPECT SYSTEMS 73

    7.4.2.1 Standalone SPECT Systems 74

    7.4.2.2 SPECT/CT Systems 75

    7.4.2.3 SPECT/MRI Systems 75

    7.4.3 TRIMODALITY (SPECT/PET/CT) SYSTEMS 76

    7.5 MICRO-MRI 76

    7.6 MICRO-ULTRASOUND 78

    7.7 MICRO-CT 79

    7.8 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS 81

    7.9 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS 82

    8 GLOBAL PRECLINICAL IMAGING MARKET, BY REAGENTS 83

    8.1 INTRODUCTION 84

    8.2 PRECLINICAL OPTICAL IMAGING REAGENTS 85

    8.2.1 BIOLUMINESCENT IMAGING REAGENTS 87

    8.2.1.1 Luciferins 90

    8.2.1.1 Proluciferins 90

    8.2.1.2 Coelenterazine 91

    8.2.1.3 Others 92

    8.2.2 FLUORESCENT IMAGING REAGENTS 92

    8.2.2.1 Green Fluorescent Proteins 95

    8.2.2.2 Red Fluorescent Proteins 95

    8.2.2.3 Infrared Dyes 96

    8.2.2.4 Others (Natural fluorescence molecules such as Collagen and Elastin) 97

    8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS 98

    8.3.1 PRECLINICAL PET TRACERS 100

    8.3.1.1 Fluorine-18-based Preclinical PET Tracers 101

    8.3.1.2 Carbon-11-based Preclinical PET Tracers 102

    8.3.1.3 Copper-64-based Preclinical PET Tracers 103

    8.3.1.4 Others 103

    8.3.2 PRECLINICAL SPECT PROBES 104

    8.3.2.1 Technetium-99m-based Preclinical SPECT Probes 106

    8.3.2.2 Iodine-131-based Preclinical SPECT Probes 107

    8.3.2.3 Gallium-67-based Preclinical SPECT Probes 107

    8.3.2.4 Thallium-201-based Preclinical SPECT Probes 108

    8.3.2.5 Others 109

    8.4 PRECLINICAL MRI CONTRAST AGENTS 109

    8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS 112

    8.4.2 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS 112

    8.4.3 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS 113

    8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS 114

    8.6 PRECLINICAL CT CONTRAST AGENTS 115

    8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS 117

    8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS 118

    8.6.3 GOLD NANOPARTICLES 118

    8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS 119

    9 GEOGRAPHIC ANALYSIS 120

    9.1 INTRODUCTION 121

    9.2 NORTH AMERICA 122

    9.3 EUROPE 126

    9.4 ASIA-PACIFIC 129

    9.5 REST OF THE WORLD (ROW) 133

    10 COMPETITIVE LANDSCAPE 136

    10.1 OVERVIEW 136

    10.2 MARKET SHARE ANALYSIS: PRECLINICAL IMAGING MARKET, BY KEY PLAYER, 2013 137

    10.3 COMPETITIVE SITUATION AND TRENDS 138

    10.3.1 NEW PRODUCT LAUNCHES AND PRODUCT DEVELOPMENTS 139

    10.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 140

    10.3.3 GEOGRAPHICAL EXPANSIONS 141

    10.3.4 MERGERS AND ACQUISITIONS 142

    10.3.5 OTHER DEVELOPMENTS 143

    11 COMPANY PROFILES 145

    11.1 INTRODUCTION 145

    11.2 PERKINELMER, INC. 145

    11.2.1 BUSINESS OVERVIEW 145

    11.2.2 PRODUCT PORTFOLIO 147

    11.2.3 KEY STRATEGY 147

    11.2.4 KEY DEVELOPMENTS (2012-2014) 148

    11.2.5 SWOT ANALYSIS 149

    11.3 BRUKER CORPORATION 150

    11.3.1 BUSINESS OVERVIEW 150

    11.3.2 PRODUCT PORTFOLIO 151

    11.3.3 KEY STRATEGY 151

    11.3.4 KEY DEVELOPMENTS (2012–2014) 152

    11.3.5 SWOT ANALYSIS 153

    11.4 FUJIFILM VISUALSONICS, INC. 154

    11.4.1 BUSINESS OVERVIEW 154

    11.4.2 PRODUCT PORTFOLIO 154

    11.4.3 KEY STRATEGY 155

    11.4.4 KEY DEVELOPMENTS (2012–2014) 155

    11.4.5 SWOT ANALYSIS 156

    11.5 MEDISO LTD. 157

    11.5.1 BUSINESS OVERVIEW 157

    11.5.2 PRODUCT PORTFOLIO 157

    11.5.3 KEY STRATEGY 157

    11.5.4 KEY DEVELOPMENTS (2012–2014) 158

    11.5.5 SWOT ANALYSIS 159

    11.6 TRIFOIL IMAGING 160

    11.6.1 BUSINESS OVERVIEW 160

    11.6.2 PRODUCT PORTFOLIO 160

    11.6.3 KEY STRATEGY 161

    11.6.4 KEY DEVELOPMENTS (2012–2014) 161

    11.7 MR SOLUTIONS LTD. 163

    11.7.1 BUSINESS OVERVIEW 163

    11.7.2 PRODUCT PORTFOLIO 163

    11.7.3 KEY STRATEGY 163

    11.7.4 KEY DEVELOPMENTS (2012-2014) 164

    11.8 ASPECT IMAGING 165

    11.8.1 BUSINESS OVERVIEW 165

    11.8.2 PRODUCT PORTFOLIO 165

    11.8.3 KEY STRATEGY 165

    11.8.4 KEY DEVELOPMENTS (2012–2014) 166

    11.9 BIOSPACE LAB S.A. 167

    11.9.1 BUSINESS OVERVIEW 167

    11.9.2 PRODUCT PORTFOLIO 167

    11.9.3 KEY STRATEGY 167

    11.9.4 KEY DEVELOPMENTS (2012–2014) 168

    11.10 LI-COR BIOSCIENCES 169

    11.10.1 BUSINESS OVERVIEW 169

    11.10.2 PRODUCT PORTFOLIO 169

    11.10.3 KEY STRATEGY 170

    11.10.4 KEY DEVELOPMENTS (2012-2014) 170

    11.11 MILABS B.V. 172

    11.11.1 BUSINESS OVERVIEW 172

    11.11.2 PRODUCT PORTFOLIO 172

    11.11.3 KEY STRATEGY 173

    11.11.4 KEY DEVELOPMENTS (2012–2014) 173

    12 APPENDIX 174

    12.1 INSIGHTS OF INDUSTRY EXPERTS 174

    12.2 DISCUSSION GUIDE* 175

    12.3 COMPANY DEVELOPMENTS (2012–2014) 179

    12.3.1 ASPECT IMAGING 179

    12.3.2 BRUKER CORPORATION 179

    12.3.3 LI-COR BIOSCIENCES 180

    12.3.4 MEDISO LTD. 182

    12.3.5 MILABS B.V. 182

    12.3.6 PERKINELMER, INC. 182

    12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 184

    12.5 AVAILABLE CUSTOMIZATIONS 185

    12.6 RELATED REPORTS 186

List Of Tables
in Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

LIST OF TABLES


TABLE 1 PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,

2012–2019 ($MILLION) 58

TABLE 2 PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 59

TABLE 3 GLOBAL OPTICAL IMAGING SYSTEMS MARKET SIZE, BY TYPE,

2012–2019 ($MILLION) 60

TABLE 4 OPTICAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 61

TABLE 5 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS MARKET SIZE,

BY REGION, 2012–2014 ($MILLION) 63

TABLE 6 STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 ($MILLION) 64

TABLE 7 OPTICAL + X-RAY/OPTICAL + CT IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 ($MILLION) 66

TABLE 8 GLOBAL PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 67

TABLE 9 PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 68

TABLE 10 GLOBAL MICRO-PET SYSTEMS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 69

TABLE 11 MICRO-PET SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 70

TABLE 12 STANDALONE PET SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 71

TABLE 13 PET/CT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 72

TABLE 14 PET/MRI SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 72

TABLE 15 GLOBAL MICRO-SPECT SYSTEMS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 73

TABLE 16 MICRO-SPECT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 74

TABLE 17 STANDALONE SPECT SYSTEMS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 74

TABLE 18 SPECT/CT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 75

TABLE 19 MICRO-MRI SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 77

TABLE 20 MICRO-ULTRASOUND SYSTEMS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 79

TABLE 21 MICRO-CT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 80

TABLE 22 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 82

TABLE 23 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,

2012–2019 ($MILLION) 84

TABLE 24 PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 85

TABLE 25 GLOBAL PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 86

TABLE 26 PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 87

TABLE 27 GLOBAL PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE,

BY TYPE, 2012–2019 ($MILLION) 88

TABLE 28 PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 89

TABLE 29 PRECLINICAL LUCIFERINS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 90

TABLE 30 PRECLINICAL PROLUCIFERINS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 91

TABLE 31 PRECLINICAL COELENTERAZINE MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 91

TABLE 32 OTHER PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 92

TABLE 33 GLOBAL PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 93

TABLE 34 PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 94

TABLE 35 PRECLINICAL GREEN FLUORESCENT PROTEINS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 95

TABLE 36 PRECLINICAL RED FLUORESCENT PROTEINS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 96

TABLE 37 PRECLINICAL INFRARED DYES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 97

TABLE 38 OTHER PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 97

TABLE 39 GLOBAL PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 98

TABLE 40 PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 99

TABLE 41 GLOBAL PRECLINICAL PET TRACERS MARKET SIZE, BY TYPE,

2012–2019 ($MILLION) 101

TABLE 42 PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 101

TABLE 43 FLUORINE-18-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 102

TABLE 44 CARBON-11-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 102

TABLE 45 COPPER-64-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 103

TABLE 46 OTHER PRECLINICAL PET TRACERS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 104

TABLE 47 GLOBAL PRECLINICAL SPECT PROBES MARKET SIZE, BY TYPE,

2012–2019 ($MILLION) 105

TABLE 48 PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 106

TABLE 49 TECHNETIUM-99M-BASED PRECLINICAL SPECT PROBES MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 106

TABLE 50 IODINE-131-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 107

TABLE 51 GALLIUM-67-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 108

TABLE 52 THALLIUM-201-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 108

TABLE 53 OTHER PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 109

TABLE 54 GLOBAL PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY TYPE,

2012–2019 ($MILLION) 110

TABLE 55 PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 111

TABLE 56 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 112

TABLE 57 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 113

TABLE 58 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 113

TABLE 59 PRECLINICAL ULTRASOUND CONTRAST AGENTS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 115

TABLE 60 GLOBAL PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY TYPE,

2012–2019 ($MILLION) 116

TABLE 61 PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION,

2012–2019 ($MILLION) 117

TABLE 62 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 117

TABLE 63 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 118

TABLE 64 GOLD NANOPARTICLES PRECLINICAL CT CONTRAST AGENTS MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 119

TABLE 65 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE,

BY REGION, 2012–2019 ($MILLION) 119

TABLE 66 GLOBAL PRECLINICAL IMAGING SYSTEMS AND REAGENTS MARKET SIZE,

BY REGION, 2012-2019 ($MILLION) 122

TABLE 67 NORTH AMERICA: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT,

2012-2019 ($MILLION) 124

TABLE 68 NORTH AMERICA: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2012-2019 ($MILLION) 125

TABLE 69 U.S.: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,

2012-2019 ($MILLION) 125

TABLE 70 NORTH AMERICA: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 126

TABLE 71 EUROPE: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT,

012-2019 ($MILLION) 128

TABLE 72 EUROPE: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,

2012-2019 ($MILLION) 129

TABLE 73 EUROPE: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,

2012-2019 ($MILLION) 129

TABLE 74 ASIA-PACIFIC: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT,

2012-2019 ($MILLION) 132

TABLE 75 ASIA-PACIFIC: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2012-2019 ($MILLION) 132

TABLE 76 ASIA-PACIFIC: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,

2012-2019 ($MILLION) 133

TABLE 77 ROW: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2012-2019 ($MILLION) 134

TABLE 78 ROW: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,

2012-2019 ($MILLION) 134

TABLE 79 ROW: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,

2012-2019 ($MILLION) 135

TABLE 80 TOP 5 NEW PRODUCT LAUNCHES AND PRODUCT DEVELOPMENTS, 2012–2014 139

TABLE 81 TOP 5 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2012–2014 140

TABLE 82 TOP 5 GEOGRAPHICAL EXPANSIONS, 2012–2014 141

TABLE 83 MERGERS AND ACQUISITIONS, 2012–2014 142

TABLE 84 TOP 5 OTHER DEVELOPMENTS, 2012–2014 144

List Of Figures, Charts and Diagrams
in Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

LIST OF FIGURES


FIGURE 1 RESEARCH DESIGN 22

FIGURE 2 BREAK DOWN OF SUPPLY SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 24

FIGURE 3 PRECLINICAL IMAGING SYSTEMS MARKET: BOTTOM UP APPROACH 26

FIGURE 4 PRECLINICAL IMAGING SYSTEMS MARKET: TOP-DOWN APPROACH 26

FIGURE 5 PRECLINICAL IMAGING REAGENTS MARKET: TOP-DOWN APPROACH 27

FIGURE 6 PRECLINICAL IMAGING MARKET: DATA TRIANGULATION 28

FIGURE 7 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, 2014 ($MILLION) 30

FIGURE 8 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, 2014 VS. 2019 32

FIGURE 9 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, 2014 VS. 2019 33

FIGURE 10 GLOBAL PRECLINICAL IMAGING MARKET, BY REGION, 2014 ($MILLION) 34

FIGURE 11 EMERGING COUNTRIES OFFERING HIGH GROWTH OPPORTUNITIES TO PLAYERS IN THE PRECLINICAL IMAGING MARKET 35

FIGURE 12 NORTH AMERICA COMMANDS THE LARGEST SHARE OF THE GLOBAL PRECLINICAL IMAGING REAGENTS MARKET 36

FIGURE 13 OPTICAL, NUCLEAR, MRI, & ULTRASOUND IMAGING SYSTEMS COMMAND THE LARGEST SHARE OF THE GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET 37

FIGURE 14 OVER 80% OF THE GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET WILL BE DOMINATED BY OPTICAL, NUCLEAR, & MRI SYSTEMS IN 2019 38

FIGURE 15 PRECLINICAL IMAGING MARKET SEGMENTATION 39

FIGURE 16 PRECLINICAL IMAGING MARKET SEGMENTATION, BY MODALITY 40

FIGURE 17 PRECLINICAL IMAGING REAGENTS MARKET SEGMENTATION, BY TYPE 41

FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 42

FIGURE 19 ADVANCEMENTS IN MOLECULAR IMAGING TECHNOLOGIES BOOSTING THE ADOPTION OF THESE SYSTEMS IN PRECLINICAL RESEARCH STUDIES 44

FIGURE 20 HIGH COST OF IMAGING SYSTEMS AND REDUCED NIH FUNDING ARE RESTRICTING THE GROWTH OF PRECLINICAL IMAGING MARKET 46

FIGURE 21 EMERGING ECONOMIES OFFERING HIGH GROWTH POTENTIAL FOR PRECLINICAL IMAGING MARKET 47

FIGURE 22 TECHNOLOGICAL LIMITATIONS OF INDIVIDUAL IMAGING MODALITIES IS A KEY GROWTH CHALLENGE FOR STANDALONE PRECLINICAL IMAGING DEVICE PROVIDERS 49

FIGURE 23 VALUE CHAIN OF PRECLINICAL IMAGING SYSTEMS MARKET 51

FIGURE 24 MARKET PLAYERS PREFER BOTH DIRECT & INDIRECT DISTRIBUTION STRATEGIES 52

FIGURE 25 PORTER’S FIVE FORCES ANALYSIS, 2014 54

FIGURE 26 PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, 2014 VS. 2019 ($MILLION): NUCLEAR IMAGING SYSTEMS MARKET TO GROW AT

THE FASTEST RATE 58

FIGURE 27 THE BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS SEGMENT HOLDS A MAJOR SHARE OF THE PRECLINICAL OPTICAL IMAGING SYSTEMS MARKET (2014) 60

FIGURE 28 THE ASIA-PACIFIC PRECLINICAL OPTICAL IMAGING SYSTEMS MARKET IS EXPECTED TO GROW AT A HIGH RATE FROM 2014 TO 2019 61

FIGURE 29 THE ASIA-PACIFIC PRECLINICAL BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS MARKET IS EXPECTED TO GROW AT A DOUBLE DIGIT RATE DURING THE FORECAST PERIOD 62

FIGURE 30 THE STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET IS EXPECTED TO WITNESS SLUGGISH GROWTH IN ALL GEOGRAPHIC REGIONS 64

FIGURE 31 DEMAND FOR OPTICAL + X-RAY/OPTICAL + CT IMAGING SYSTEMS IS EXPECTED TO GROW RAPIDLY IN THE ASIA-PACIFIC REGION 65

FIGURE 32 THE MICRO-PET SYSTEMS SEGMENT HOLDS THE LARGEST SHARE OF THE PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET IN 2014 67

FIGURE 33 NORTH AMERICA COVERS THE LARGEST SHARE OF THE PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET IN 2014 68

FIGURE 34 PET/MRI SYSTEMS MARKET IS EXPECTED TO GROW AT A DOUBLE-DIGIT RATE DURING THE FORECAST PERIOD 69

FIGURE 35 ASIA-PACIFIC IS EXPECTED TO OUTPACE THE EUROPEAN MICRO-PET SYSTEMS MARKET BY 2019 70

FIGURE 36 NORTH AMERICA WILL CONTINUE TO DOMINATE THE MICRO-SPECT SYSTEMS MARKET IN THE NEXT FIVE YEARS 73

FIGURE 37 THE ASIA-PACIFIC MICRO-MRI SYSTEMS MARKET IS EXPECTED TO EQUAL THE MARKET SIZE OF THE NORTH AMERICAN MARKET BY 2019 77

FIGURE 38 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL MICRO-ULTRASOUND SYSTEMS MARKET BY 2019 78

FIGURE 39 NORTH AMERICA HOLDS THE LARGEST SHARE OF THE GLOBAL MICRO-CT SYSTEMS MARKET IN 2014 80

FIGURE 40 NORTH AMERICA IS EXPECTED TO BE THE SECOND-FASTEST-GROWING MARKET FOR PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS AFTER ASIA-PACIFIC DURING THE FORECAST PERIOD 81

FIGURE 41 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, 2014 VS. 2019 ($MILLION): MRI CONTRAST AGENTS MARKET TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 84

FIGURE 42 BIOLUMINESCENT IMAGING REAGENTS SEGMENT WILL CONTINUE TO DOMINATE THE PRECLINICAL OPTICAL IMAGING REAGENTS MARKET IN THE FORECAST PERIOD 85

FIGURE 43 ASIA-PACIFIC PRECLINICAL OPTICAL IMAGING REAGENTS MARKET IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE NEXT FIVE YEARS 86

FIGURE 44 LUCIFERINS TO COMMAND THE LARGEST SHARE OF BIOLUMINESCENT IMAGING REAGENTS MARKET IN 2014 88

FIGURE 45 ASIA-PACIFIC REGION IS ESTIMATED TO WITNESS THE HIGHEST GROWTH RATE IN THE BIOLUMINESCENT IMAGING REAGENTS MARKET 89

FIGURE 46 INFRARED DYES ACCOUNT FOR THE LARGEST SHARE OF PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET IN 2014 93

FIGURE 47 ASIA-PACIFIC AND ROW REGIONS WILL DRIVE THE GROWTH OF PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET DURING THE FORECAST PERIOD 94

FIGURE 48 PET TRACERS WILL CONTINUE TO DOMINATE THE PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET IN THE NEXT FIVE YEARS 98

FIGURE 49 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE GLOBAL PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET IN 2014 99

FIGURE 50 FLUORINE-18-BASED PET TRACERS COMMAND THE LION’S SHARE OF PRECLINICAL PET TRACERS MARKET IN 2014 100

FIGURE 51 TECHNETIUM-99M-BASED SPECT PROBES COMMAND THE LION’S SHARE OF PRECLINICAL SPECT PROBES MARKET IN 2014 105

FIGURE 52 GADOLINIUM-BASED MRI CONTRAST AGENTS COMMAND THE LARGEST SHARE OF PRECLINICAL MRI CONTRAST AGENTS MARKET IN 2014 110

FIGURE 53 ASIA-PACIFICA MRI CONTRAST AGENTS MARKET IS ESTIMATED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 111

FIGURE 54 NORTH AMERICA ACCOUNTS FOR THE MAJOR SHARE OF THE PRECLINICAL ULTRASOUND CONTRAST AGENTS MARKET IN 2014 114

FIGURE 55 IODINE-BASED CONTRAST AGENTS HOLD THE LARGEST SHARE OF PRECLINICAL CT CONTRAST AGENTS MARKET IN 2014 116

FIGURE 56 PRECLINICAL IMAGING MARKET, BY REGION, 2014 VS. 2019 ($MILLION): ASIA-PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 121

FIGURE 57 NORTH AMERICAN PRECLINICAL IMAGING MARKET SNAPSHOT (2014-2019): GROWTH IS DRIVEN BY HIGH ADOPTION OF INNOVATIVE TECHNOLOGIES 123

FIGURE 58 EUROPEAN PRECLINICAL IMAGING MARKET SNAPSHOT (2014-2019): GROWTH IS DRIVEN BY INCREASED GOVERNMENT FUNDING FOR DEVELOPING EUROPEAN RESEARCH SECTOR 127

FIGURE 59 ASIA-PACIFIC PRECLINICAL IMAGING MARKET SNAPSHOT (2014-2019): GROWTH IS DRIVEN BY RISING GOVERNMENT INVESTMENT IN PHARMACEUTICAL R&D 130

FIGURE 60 LEADING MARKET PLAYERS ADOPTED NEW PRODUCT LAUNCHES AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS (2012–2014) 136

FIGURE 61 GLOBAL PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2013 137

FIGURE 62 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES IS THE KEY STRATEGY 138

FIGURE 63 PRECLINICAL IMAGING SYSTEMS PORTFOLIO MIX OF TOP 5 MARKET PLAYERS 145

FIGURE 64 PERKINELMER, INC.: COMPANY SNAPSHOT 146

FIGURE 65 BRUKER CORPORATION: COMPANY SNAPSHOT 150

FIGURE 66 FUJIFILM HOLDINGS CORPORATION.: COMPANY SNAPSHOT 154

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

41282 | MD 3117

Number of Pages

187

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016
The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 report pr...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Ingenuity Systems, Inc. - Medical Equipment - Deals and Alliances Profile
SummaryIngenuity Systems, Inc. (Ingenuity), a subsidiary of Qiagen N.V. is a medical technology comp...
16 Oct 2015 by Global Data USD $250 More Info
Bracco Imaging S.p.A. - Medical Equipment - Deals and Alliances Profile
SummaryBracco Imaging S.p.A. (Bracco), a subsidiary of Bracco S.p.A. is a diagnostic imaging service...
16 Oct 2015 by Global Data USD $250 More Info
Advanced Data Systems Corporation - Medical Equipment - Deals and Alliances Profile
SummaryAdvanced Data Systems Corporation (Advanced Data Systems) is a healthcare IT company. The com...
15 Oct 2015 by Global Data USD $250 More Info
3M Health Information Systems, Inc. - Medical Equipment - Deals and Alliances Profile
Summary3M Health Information Systems, Inc. (3M HIS) a subsidiary of 3M Company is a healthcare servi...
15 Oct 2015 by Global Data USD $250 More Info
Clinical Trial Design for Commercial Success
IntroductionClinical Trial Design for Commercial Success offers expert insights on how to best posit...
01 Jun 2015 by FirstWord Pharma USD $695 More Info
Epigenetic Proteins & Reagents Trends 2015
HTStec's Epigenetic Proteins & Reagents Trends 2015 report was published on 1 April 2015. This 66 pa...
01 Apr 2015 by HTStec USD $2,000 More Info
Designing Clinical Trials to Show Value
IntroductionOnce, they were the benchmark for product development. But these days, randomised contro...
01 Jan 2014 by FirstWord Pharma USD $695 More Info
The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
IntroductionClinical guidelines are taking hold in the practice of medicine. Though not always volun...
01 Feb 2013 by FirstWord Pharma USD $695 More Info
Tapping Social Media for Clinical Trial Recruitment
IntroductionWith an estimated 80% of all clinical trials failing to achieve enrolment goals, sponsor...
01 Apr 2012 by FirstWord Pharma USD $695 More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...